CTSS and CD53: Emerging m6A methylation markers in diabetic kidney disease pathogenesis and their clinical implications

CTSS 和 CD53:糖尿病肾病发病机制中新兴的 m6A 甲基化标志物及其临床意义

阅读:3

Abstract

OBJECTIVE: Diabetic kidney disease (DKD) is increasingly recognized as a leading cause of chronic kidney disease (CKD) worldwide. Although N6-methyladenosine (m6A) mRNA modification is abundant in eukaryotes, its specific contribution to DKD pathogenesis is not well understood. This study aims to investigate the role of N6-methyladenosine (m6A) RNA modification patterns in DKD and their relationship with immune regulation. METHODS: Three GEO datasets were analyzed to explore m6A modification patterns. Random forest modeling and consensus clustering were used for subtype identification. Immune cell infiltration was evaluated using ssGSEA. Key candidate genes were refined through LASSO regression and experimental verification in diabetic mouse models via qPCR. RESULTS: Eight differentially expressed m6A regulators were identified in DKD. Two distinct m6A modification patterns were established, with cluster B showing enhanced immune cell infiltration. WTAP positively correlated with immune cell populations, while YTHDC2 showed negative correlations. CTSS and CD53 were identified as potential biomarkers and validated in diabetic mouse models, showing negative correlations with glomerular filtration rate. CONCLUSIONS: This study reveals two m6A methylation patterns in DKD, with one associated with increased immune infiltration. We identified CTSS and CD53 as hub genes and validated them in diabetic mouse kidney tissues, suggesting their potential as clinical biomarkers for DKD. CLINICAL TRIAL NUMBER: Not applicable.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。